<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800614</url>
  </required_header>
  <id_info>
    <org_study_id>516-009</org_study_id>
    <nct_id>NCT04800614</nct_id>
  </id_info>
  <brief_title>A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib</brief_title>
  <official_title>An Open-label, Randomized, Three-period, Crossover Study of the Effect of Food on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-label, Randomized, Three-period, Crossover Study of the Effect of Food on the&#xD;
      Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Actual">July 6, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Three Period Crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics - Cmax (sitravatinib)</measure>
    <time_frame>Up to 72 hours after dosing</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUCâˆž (sitravatinib)</measure>
    <time_frame>Up to 72 hours after dosing</time_frame>
    <description>Area under the plasma concentration-time curve from time zero extrapolated to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - AUClast (sitravatinib)</measure>
    <time_frame>Up to 72 hours after dosing</time_frame>
    <description>AUC from time zero to the last measured time point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 44 days</time_frame>
    <description>Incidence and severity of adverse events (AEs) dosed in the fasted and fed states in healthy adult subjects</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>Fasted dosing followed by fed dosing (high-fat meal) followed by fed dosing (low-fat meal)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing in the fasted state followed by fed dosing after high and low fat meals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fasted dosing followed by fed dosing (low-fat meal) followed by fed dosing (high-fat meal)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing in the fasted state followed by fed dosing after low and high fat meals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fed dosing (high-fat meal) followed by fasted dosing followed by fed dosing (low-fat meal)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing after a high-fat meal followed by doing in the fasted sate followed by dosing after a low-fat meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fed dosing (high-fat) followed by fed dosing (low-fat) followed by dosing in the fasted state</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fed dosing (high-fate meal) followed by fed dosing (low-fate meal) followed by dosing in the fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fed dosing (low-fat) followed dosing in the fasted state followed by fed dosing (high fat)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fed dosing (low-fat) meal followed dosing in the fasted state followed by fed dosing (high-fat meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fed dosing (low-fat) followed by fed dosing (high-fat) followed by dosing in the fasted state</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fed dosing after a low-fat and high-fate meals followed by dosing in the fasted state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitravatinib</intervention_name>
    <description>100 mg sitravatinib on Day 1 of each of 3 periods</description>
    <arm_group_label>Fasted dosing followed by fed dosing (high-fat meal) followed by fed dosing (low-fat meal)</arm_group_label>
    <arm_group_label>Fasted dosing followed by fed dosing (low-fat meal) followed by fed dosing (high-fat meal)</arm_group_label>
    <arm_group_label>Fed dosing (high-fat meal) followed by fasted dosing followed by fed dosing (low-fat meal)</arm_group_label>
    <arm_group_label>Fed dosing (high-fat) followed by fed dosing (low-fat) followed by dosing in the fasted state</arm_group_label>
    <arm_group_label>Fed dosing (low-fat) followed by fed dosing (high-fat) followed by dosing in the fasted state</arm_group_label>
    <arm_group_label>Fed dosing (low-fat) followed dosing in the fasted state followed by fed dosing (high fat)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index between 18.0 and 32.0 kg/m2, inclusive.&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory&#xD;
             evaluations at screening and/or check-in&#xD;
&#xD;
          -  Females of childbearing potential will not be pregnant or lactating and must have a&#xD;
             negative result on an approved pregnancy test at screening and check-in. Females of&#xD;
             childbearing potential must agree to use contraception&#xD;
&#xD;
          -  Male subjects must agree to use contraception&#xD;
&#xD;
          -  Able to comprehend and willing to sign an ICF and to abide by the study restrictions&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of drug/chemical abuse within 2 years prior to screening.&#xD;
&#xD;
          -  History of alcohol abuse within 12 months prior to screening&#xD;
&#xD;
          -  Positive urine drug screen at screening or check-in or positive alcohol test at&#xD;
             check-in.&#xD;
&#xD;
          -  Use of tobacco- or nicotine-containing products or e-cigarettes (with or without&#xD;
             nicotine) within 3 months prior to check-in for Period 1; or positive cotinine at&#xD;
             screening or check-in.&#xD;
&#xD;
          -  Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 30 days prior to study drug administration on Day 1&#xD;
             of Period 1.&#xD;
&#xD;
          -  Use or intend to use any medications/products known to alter drug absorption,&#xD;
             metabolism, or elimination processes, including St. John's wort, within 30 days prior&#xD;
             to study drug administration on Day 1 of Period 1.&#xD;
&#xD;
          -  Use or intend to use any prescription medications/products within 14 days prior to&#xD;
             study drug administration on Day 1 of Period 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance Clinical Research Unit, Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

